Free Trial

Metsera (MTSR) Competitors

Metsera logo
$40.47 +0.82 (+2.07%)
As of 07/25/2025 04:00 PM Eastern

MTSR vs. GMAB, MRNA, RDY, VTRS, ASND, QGEN, VRNA, BBIO, BPMC, and ROIV

Should you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

Metsera vs. Its Competitors

Metsera (NASDAQ:MTSR) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Genmab A/S has a net margin of 35.11% compared to Metsera's net margin of 0.00%. Genmab A/S's return on equity of 18.08% beat Metsera's return on equity.

Company Net Margins Return on Equity Return on Assets
MetseraN/A N/A N/A
Genmab A/S 35.11%18.08%14.52%

Genmab A/S has higher revenue and earnings than Metsera.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetseraN/AN/A-$209.13MN/AN/A
Genmab A/S$3.12B4.82$1.14B$1.7613.30

Metsera currently has a consensus target price of $55.00, suggesting a potential upside of 35.90%. Genmab A/S has a consensus target price of $37.80, suggesting a potential upside of 61.54%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Metsera.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Metsera
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Genmab A/S
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.64

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Metsera had 3 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Metsera and 5 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 1.27 beat Metsera's score of 0.93 indicating that Genmab A/S is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Metsera
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Genmab A/S
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Genmab A/S beats Metsera on 11 of the 13 factors compared between the two stocks.

Get Metsera News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MTSR vs. The Competition

MetricMetseraMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.17B$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E RatioN/A21.1828.1020.05
Price / SalesN/A288.50432.4490.07
Price / CashN/A42.7636.2258.56
Price / Book-16.458.378.665.87
Net Income-$209.13M-$55.19M$3.25B$258.55M
7 Day Performance-5.24%5.88%4.23%3.74%
1 Month Performance40.96%17.33%10.52%11.75%
1 Year PerformanceN/A4.42%34.41%18.03%

Metsera Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTSR
Metsera
N/A$40.47
+2.1%
$55.00
+35.9%
N/A$4.17BN/A0.0081Lockup Expiration
Gap Down
GMAB
Genmab A/S
4.0806 of 5 stars
$21.88
-0.6%
$37.80
+72.8%
-16.8%$14.12B$3.12B12.432,682Positive News
MRNA
Moderna
4.2995 of 5 stars
$31.26
-2.9%
$46.61
+49.1%
-71.6%$12.45B$3.24B-3.585,800Upcoming Earnings
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7434 of 5 stars
$14.48
-1.4%
$16.95
+17.1%
-9.3%$12.26B$3.81B21.9427,811Earnings Report
VTRS
Viatris
2.4337 of 5 stars
$8.88
-4.2%
$10.40
+17.1%
-20.0%$10.88B$14.74B-2.8032,000
ASND
Ascendis Pharma A/S
3.4327 of 5 stars
$169.90
-4.1%
$223.07
+31.3%
+24.6%$10.83B$393.54M-27.051,017Analyst Revision
QGEN
Qiagen
3.5861 of 5 stars
$48.35
+0.2%
$49.40
+2.2%
+26.1%$10.72B$1.98B121.235,765Analyst Downgrade
Analyst Revision
High Trading Volume
VRNA
Verona Pharma PLC American Depositary Share
2.8206 of 5 stars
$104.90
+0.1%
$109.00
+3.9%
+375.4%$8.92B$42.28M-52.4530Positive News
BBIO
BridgeBio Pharma
4.6357 of 5 stars
$46.51
-0.5%
$61.20
+31.6%
+73.4%$8.88B$221.90M-13.18400Analyst Downgrade
BPMC
Blueprint Medicines
1.0836 of 5 stars
$129.46
flat
$128.25
-0.9%
N/A$8.36B$562.12M-52.41640Positive News
Upcoming Earnings
ROIV
Roivant Sciences
2.5987 of 5 stars
$11.44
-1.8%
$16.50
+44.2%
+7.5%$7.92B$29.05M-45.76860News Coverage
Positive News
Insider Trade

Related Companies and Tools


This page (NASDAQ:MTSR) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners